BIA Separations d.o.o.

March 22, 2005 02:49 ET

Plasmid DNA Manufacturing Technology-Co-Developed by Boehringer Ingelheim Austria with BIA Separations


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: BIA SEPARATIONS D.O.O.

MARCH 22, 2005 - 02:49 ET

Plasmid DNA Manufacturing Technology-Co-Developed by
Boehringer Ingelheim Austria with BIA Separations

VIENNA, AUSTRIA and LJUBLJANA, SLOVENIA--(CCNMatthews - March 22, 2005)
- Boehringer Ingelheim Austria GmbH, Vienna, and BIA Separations d.o.o.,
Ljubljana, are pleased to announce a technological innovation in the
field of plasmid DNA (pDNA) manufacture.

To meet the growing need for pharmaceutical grade pDNA, Boehringer
Ingelheim Austria has developed a high cell density fermentation
technology achieving titers up to 1 g pDNA per Liter, and has
specifically designed equipment for the automated and gentle lysis of
the biomass. A key and novel element of the production process is the
use of CIM Convection Interaction Media® short monolithic columns for
the purification of pDNA. The fast separation speed, outstanding
capacity, and excellent separation power of CIM® columns, developed by
BIA Separations, allows a 15-fold increase in productivity compared to
traditional supports. "Our customers clearly benefit from this new
development as the process is free of antibiotics, animal-derived raw
materials, enzymes and organic solvents and employs the powerful CIM®
separation technology" says Dr. Kurt Konopitzky, Head of the Division
Biopharmaceuticals/Operations at Boehringer Ingelheim Austria.

Boehringer Ingelheim Austria and BIA Separations are committed to
developing manufacturing technology that leads to innovative
biopharmaceuticals. The process produces pDNA on a large scale and
follows Good Manufacturing Practice for clinical and commercial
applications.

After successfully co-developing this novel process, the two companies
are collaborating on a non-exclusive basis where BIA Separations will
supply Boehringer Ingelheim Austria with CIM® columns.

About Boehringer Ingelheim Austria

Boehringer Ingelheim Austria GmbH belongs to the international
Boehringer Ingelheim Corporation which is one of the world's 20 leading
pharmaceutical companies. Since 1885, the family-owned company has been
committed to researching, developing, manufacturing and marketing novel
products of high therapeutic value for human and veterinary medicine.
More info can be found at www.boehringer-ingelheim.com

About BIA Separations

BIA Separations is the only worldwide manufacturer of Short Monolithic
Columns optimized to meet the research and production needs of the
biotechnology industry. CIM® are the first monoliths used for the
industrial scale purification of proteins, DNAs and virus particles.
Headquartered in the Slovenian capital of Ljubljana, the company
consists of research, production, and analytical labs. More information
is available at www.monoliths.com.

-30-

Contact Information